中国卒中杂志 ›› 2019, Vol. 14 ›› Issue (05): 468-473.DOI: 10.3969/j.issn.1673-5765.2019.05.012
熊荣,黄光
收稿日期:
2019-02-22
出版日期:
2019-05-20
发布日期:
2019-05-20
通讯作者:
黄光 hsmmt@sina.com
Received:
2019-02-22
Online:
2019-05-20
Published:
2019-05-20
摘要:
主动脉瓣狭窄是老年人最常见瓣膜疾病,主动脉瓣置换术成功地降低了该病的死亡率并 极大提高了患者的生活质量。主动脉瓣膜置换术后卒中为其常见并发症,可能与手术操作、病变瓣膜 区凝血及抗凝血系统失衡等因素相关。有效的抗栓药物治疗及脑保护装置的使用可减少卒中的发生。 本文就主动脉瓣膜置换术相关卒中的发病率、发病机制及预防措施进行综述,旨在为临床治疗和预 防卒中提供帮助。
熊荣,黄光. 主动脉瓣膜置换术后卒中研究进展[J]. 中国卒中杂志, 2019, 14(05): 468-473.
XIONG Rong, HUANG Guang. Advance in Stroke after Aortic Valve Replacement[J]. Chinese Journal of Stroke, 2019, 14(05): 468-473.
[1] NKOMO V T,GARDIN J M,SKELTON T N,etal. Burden of valvular heart diseases:a populationbasedstudy[J]. Lancet,2006,368(9540):1005-1011.[2] BACH D S,SIAO D,GIRARD S E,et al.Evaluation of patients with severe symptomaticaortic stenosis who do not undergo aortic valvereplacement:the potential role of subjectivelyoverestimated operativerisk[J]. Circ Cardiovasc QualOutcomes,2009,2(6):533-539.[3] CRIBIER A,ELTCHANINOFF H,BASH A,et al.Percutaneous transcatheter implantation of an aorticvalve prosthesis for calcific aortic stenosis:firsthuman case description[J]. Circulation,2002,106(24):3006-3008.[4] MESSÉS R,ACKER M A,KASNER S E,et al.Stroke after aortic valve surgery:results from aprospective cohort[J]. Circulation,2014,129(22):2253-2261.[5] O’BRIEN S M,SHAHIAN D M,FILARDOG,et al. The Society of Thoracic Surgeons 2008cardiac surgery risk models:part 2--isolated valvesurgery[J/OL]. Ann Thorac Surg,2009,88(1Suppl):23-42. https://linkinghub.elsevier.com/retrieve/pii/S0003497509010595. DOI:10.1016/j.athoracsur.2009.05.056.[6] HAMM C W,MOLLMANN H,HOLZHEY D,etal. The German Aortic Valve Registry(GARY):inhospitaloutcome[J]. Eur Heart J,2014,35(24):1588-1598.[7] ElBARDISSI A W,SHEKAR P,COUPER G S,etal. Minimally invasive aortic valve replacement inoctogenarian,high-risk,transcatheter aortic valveimplantation candidates[J]. J Thorac CardiovascSurg,2011,141(2):328-335.[8] THOURANI V H,AILAWADI G,SZETO W Y,etal. Outcomes of surgical aortic valve replacement inhigh-risk patients:a multiinstitutional study[J]. AnnThorac Surg,2011,91(1):49-55.[9] LIKOSKY D S,SORENSEN M J,DACEY L J,et al. Long-term survival of the very elderly undergoingaortic valve surgery[J/OL]. Circulation,2009,120(11 Suppl):127-133. https://doi.org/10.1161/CIRCULATIONAHA.108.842641.[10] SMITH C R,LEON M B,MACK M J,etal. Transcatheter versus surgical aortic-valvereplacement in high-risk patients[J]. N Engl J Med,2011,364(23):2187-2198.[11] MACK M J,LEON M B,SMITH C R,et al. 5-Yearoutcomes of transcatheter aortic valve replacementor surgicalaortic valve replacement for high surgicalrisk patients with aortic stenosis(PARTNER 1):arandomised controlled trial[J]. Lancet,2015,385(9986):2477-2484.[12] THOMAS M,SCHYMIK G,WALTHER T,etal. One-year outcomes of cohort 1 in the EdwardsSAPIEN Aortic Bioprosthesis European Outcome(SOURCE)registry:the European registry oftranscatheter aortic valve implantation using theEdwards SAPIEN valve[J]. Circulation,2011,124(4):425-433.[13] MACK M J,BRENNAN J M,BRINDIS R,etal. Outcomes following transcatheter aortic valvereplacement in the United States[J]. JAMA,2013,310(19):2069-2077.[14] GILARD M,ELTCHANINOFF H,IUNG B,et al.Registry of transcatheter aortic-valve implantation inhigh-risk patients[J]. N Engl J Med,2012,366(18):1705-1715.[15] MOAT N E,LUDMAN P,DE BELDER M A,etal. Long-term outcomes after transcatheter aorticvalve implantation in high-risk patients with severeaortic stenosis:the U. K. TAVI(United KingdomTranscatheter Aortic Valve Implantation)Registry[J].J Am Coll Cardiol,2011,58(20):2130-2138.[16] ZHAO Q M,LOGNONE T,lVASCAU C,etal. Procedural results and 30-day clinical eventsanalysis following Edwards transcatheter aorticvalve implantation in 48 consecutive patients:initialexperience[J]. Clin Med J(Engl),2012,125(16):2807-2810.[17] HE W,HUANG R R,SHI Q Y,et al.Bispectralindex-guided sedation in transfemoral transcatheteraortic valve implantation:a retrospective controlstudy [J]. J Zhejiang Univ-Sci B(Biomed &Biotechnol),2017,18(4):353-359.[18] IOANNIS M,MIKKEL M S,GEORGE D D,et al.Stroke After Transcatheter Aortic Valve Replacement:Incidence,Risk Factors,Prognosis,and PreventiveStrategies[J]. Clin Cardiol,2014,37(12):756-764.[19] JAKOBSEN L,TERKELSEN C J,SØNDERGAARD L,et al. Short- and long-termmortality and stroke risk after transcatheter aorticvalve implantation[J]. Am J Cardiol,2018,121(1):78-85.[20] TAY E L,GURVITCH R,WIJESINGHE N,et al.A high-risk periodfor cerebrovascular events existsafter transcatheter aortic valve implantation[J].JACC Cardiovasc Interv,2011,4(12):1290-1297.[21] MILLER D C,BLACKSTONE E H,MACK M J,et al. Transcatheter(TAVR)versus surgical(AVR)aortic valve replacement:occurrence,hazard,riskfactors,and consequences of neurologic events inthe PARTNER trial[J]. J Thorac Cardiovasc Surg,2012,14(3):832-843.[22] ADAMS D H,POPMA J J,REARDON M J.Transcatheter aortic-valve replacement with a selfexpandingprosthesis[J]. N Engl J Med,2014,371(10):967-968.[23] KAHLERT P,KNIPP S C,SCHLAMANN M,etal. Silent and apparent cerebral ischemia afterpercutaneous transfemoral aortic valve implantation:a diffusion-weighted magnetic resonance imagingstudy[J]. Circulation,2010,121(7):870-878.[24] STORTECKY S,WINDECKER S. Stroke:aninfrequent but devastating complication incardiovascular interventions[J]. Circulation,2012,126(25):2921-2924.[25] ALASSAR A,ROY D,VALENCIA O,et al.Cerebral Embolization during transcatheter aorticvalve implantation compared with surgical aorticvalve replacement[J/OL]. Interact Cardio VascThorac Surg,2013,17(2):S134-S135. https://doi.org/10.1093/icvts/ivt372.268.[26] VAN DER LINDEN J,CASIMIR-AHN H. When docerebral emboli appear during open heart operations?A transcranial Doppler study[J]. Ann Thorac Surg,1991,51(2):237-241.[27] VAN MIEGHEM N M,SCHIPPER M E,LADICHE,et al. Histopathology of embolic debris capturedduring transcatheter aortic valve replacement[J].Circulation,2013,127(22):2194-2201.[28] HYNES B G,ROD ES-CABAU J. Transcatheteraortic valve implantation and cerebrovascular events:the current state of the art[J/OL]. Ann N Y Acad Sci,2012,1254:151-163. https://doi.org/10.1111/j.1749-6632.2012.06477.x.[29] MARECHAUX S,CORSEAUX D,VINCENTELLIA,et al. Identification of tissue factor inexperimental aortic valve sclerosis[J]. CardiovascPathol,2009,18(2):67-76.[30] NOMBELA-FRANCO L,WEBB J G,DE JAEGERE P P,et al. Timing,predictive factors,andprognostic value of cerebrovascular eventsin a largecohort of patients undergoing transcatheter aorticvalve implantation[J]. Circulation,2012,126(25):3041-3053.[31] WOLF P A,D’AGOSTINO R B,BELANGER AJ,et al. Probability of stroke:a risk profile from theFramingham Study[J]. Stroke,1991,22(3):312-318.[32] NISHIMURA R A,OTTO C M,BONOW R O,etal. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients withvalvular heart disease:a report of the AmericanCollege of Cardiology/American Heart AssociationTask Force on Clinical Practice Guidelines[J]. J AmColl Cardiol,2017,70(2):252-289.[33] WHITLOCK R P,SUN J C,FREMES S E,et al.Antithrombotic and thrombolytic therapy for valvulardisease:Antithrombotic Therapy and Preventionof Thrombosis,9th ed:American College ofChest Physicians Evidence-Based Clinical PracticeGuidelines[J/OL]. Chest,2012,141(2 Suppl):576-600. https://linkinghub.elsevier.com/retrieve/pii/S0012369212601329. DOI:10.1378/chest.11-2305.[34] TURPIE A G,GENT M,LAUPACIS A,et al. Acomparison of aspirin with placebo in patients treatedwith warfarin after heart-valve replacement[J]. N EnglJ Med,1993,329(8):524-529.[35] EIKELBOOM J W,CONNOLLY S J,BRUECKMANN M,et al. RE-ALIGN Investigators.Dabigatran versus warfarin in patients withmechanical heart valves[J]. N Engl J Med,2013,369(13):1206-1214.[36] RIAZ H,ALANSARI S A,KHAN M S,et al.Safety and use of anticoagulation after aortic valvereplacement with bioprostheses:a meta-analysis[J].Circ Cardiovasc Qual Outcomes,2016,9(3):294-302.[37] BOLOTIN G,HUBER C H,SHANI L,et al. Novelemboli protection system during cardiac surgery[J].Ann Thorac Surg,2014,98(5):1627-1633.[38] MACK M J,ACKER M A,GELIJNS A C,et al.Effect of cerebral embolic protection devices onCNS infarction in surgical aortic valve replacementa randomized clinical trial[J]. JAMA,2017,318(6):536-547.[39] USSIA G P,SCARABELLI M,MULE M,etal. Dual antiplatelet therapy versus aspirin alonein patients undergoing transcatheter aortic valveimplantation[J]. Am J Cardiol,2011,108(12):1772-1776.[40] DURAND E,BLANCHARD D,CHASSAINGS,et al. Comparison of two antiplatelet therapystrategies in patients undergoing transcatheter aorticvalve implantation[J]. Am J Cardiol,2014,113(2):355-360.[41] OTTO C M,DHARAM J K,KAREN P,et al.2017 ACC expert consensus decision pathwayfor transcatheter aortic valve replacement in themanagement of adults with aortic stenosis:a reportof the American College of Cardiology Task Forceon Clinical Expert Consensus Documents[J]. J AmColl Cardiol,2017,69(10):1313-1346.[42] CHAKRAVARTY T,SøNDERGAARD L,FRIEDMAN J,et al. Subclinical leaflet thrombosisin surgical and transcatheter bioprosthetic aorticvalves:an observational study[J]. The Lancet,2017,389(10087):2383-2392.[43] MAKKAR R R,FONTANA G,JILAIHAWIH,et al. Possible subclinical leaflet thrombosis inbioprosthetic aortic valves[J]. N Engl J Med,2015,373(16):2015-2024.[44] MERIE C,KOBER L,SKOVOLSEN P,et al.Association of warfarin therapy duration afterbioprosthetic aortic valve replacement with riskof mortality,thromboembolic complications,andbleeding[J]. JAMA,2012,308(20):2118-2125.[45] KALICH B A,ALLENDER J E,HOLLIS I B.Medication Management of Patients UndergoingTranscatheter Aortic Valve Replacement[J].Pharmacotherapy,2018,38(1):122-138.[46] VAN MIEGHEM N M,TCHETCHE D,CHIEFFOA,et al. Incidence,predictors,and implicationsof access site complications with transfemoraltranscatheter aortic valve implantation[J]. Am JCardiol,2012,110(9):1361-1367.[47] GHANEM A,KOCUREK J,SINNING J M,et al.Novel approaches for prevention of stroke related totranscatheter aortic valve implantation[J]. ExpertRev Cardiovasc Ther,2013,11(10):1311-1320.[48] ABDUL-JAWAD ALTISENT O,PURI R,RODESCABEAUJ. Embolic protection devices during TAVI:current evidence and uncertainties[J]. Rev EspCardiol(Engl Ed),2016,69(10):962-972. |
[1] | 曹黎明, 任力杰. 急性缺血性卒中诊疗技术的进展与展望[J]. 中国卒中杂志, 2024, 19(9): 983-989. |
[2] | 符鹏程, 曹黎明, 朱佳倩, 赵桂玉, 徐格林. 大动脉粥样硬化性缺血性卒中再灌注治疗的研究进展[J]. 中国卒中杂志, 2024, 19(9): 1004-1011. |
[3] | 张丽苹, 曹黎明, 肖楠, 廖雨琦, 池枫, 余艳妮, 任力杰. 纳米材料在缺血性卒中诊疗中的研究进展及挑战[J]. 中国卒中杂志, 2024, 19(9): 1012-1017. |
[4] | 姜河, 王珵, 陈祥华, 许春香. 五种院前卒中筛查量表对院内急性大血管闭塞性缺血性卒中的预测价值[J]. 中国卒中杂志, 2024, 19(9): 1018-1024. |
[5] | 王晓蕊, 骆嵩, 邹良玉, 屈洪党, 崔雪, 赵玉洁. 嗜酸性粒细胞与单核细胞比值预测急性缺血性卒中患者静脉溶栓预后的价值研究 [J]. 中国卒中杂志, 2024, 19(9): 1025-1033. |
[6] | 王铄, 余苹, 张宁, 王春雪. 2013—2023年缺血性卒中与睡眠相关性研究的文献计量学分析 [J]. 中国卒中杂志, 2024, 19(9): 1040-1047. |
[7] | 周宏宇, 李子孝, 王拥军. 基于影像组学预测大脑年龄与缺血性卒中的研究进展[J]. 中国卒中杂志, 2024, 19(9): 1066-1076. |
[8] | 阿娜古丽·阿不拉尼压孜, 吴晓欣, 李骄星, 李竹浩, 盛文利. 急性缺血性卒中磁敏感血管征影响因素及临床应用的研究进展[J]. 中国卒中杂志, 2024, 19(9): 1077-1085. |
[9] | 杨金波, 张聪. 高分辨率血管壁成像在缺血性卒中患者中的应用进展[J]. 中国卒中杂志, 2024, 19(9): 1086-1093. |
[10] | 吴春艳, 尹雅诗, 王广志, 岳奎涛. 急性缺血性卒中不同时间窗影像学评价及应用进展[J]. 中国卒中杂志, 2024, 19(9): 1094-1101. |
[11] | 王也, 魏宸铭, 李秀丽, 武剑. 多元化教学模式在大学附属教学医院卒中绿色通道培训中的应用[J]. 中国卒中杂志, 2024, 19(9): 1102-1109. |
[12] | 单凯, 赵梦, 王春娟, 李子孝, 王晓岩. 卒中及共患疾病诊疗模式探索与实践 [J]. 中国卒中杂志, 2024, 19(8): 863-865. |
[13] | 张梦若, 徐守臣, 隋翠翠, 李玉奎, 王雪莉. 下肢康复机器人联合头针治疗对老年缺血性卒中患者步行效率和协调功能影响调查 [J]. 中国卒中杂志, 2024, 19(8): 902-908. |
[14] | 薛明月, 张慧鑫, 苏丹, 李丽霞, 李晶玮, 李虹. 缺血性卒中患者服药依从性影响因素分析 [J]. 中国卒中杂志, 2024, 19(8): 909-914. |
[15] | 吴娱倩, 张玉梅, 臧大维, 范小伟, 王安心, 张晓丽, 孟霞. 上肢动作研究测试量表评定亚急性期缺血性卒中患者偏瘫侧上肢及手功能的信效度和敏感性研究 [J]. 中国卒中杂志, 2024, 19(8): 915-923. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||